What is the main difference between KLOW and GLOW?

KPV is the only compositional difference. GLOW contains BPC-157, TB-500, and GHK-Cu. KLOW contains those same three peptides plus KPV, a three-amino-acid fragment studied for inflammatory signaling in cell systems and mouse colitis models. That addition changes the rationale, but no head-to-head trial shows that KLOW produces better outcomes.

What does KPV add to KLOW?

KPV adds a preclinical inflammation-focused mechanism. Laboratory work found that it entered intestinal and immune cells through PepT1 and reduced NF-kappaB, MAP-kinase, and cytokine signaling; mouse colitis studies reported lower inflammatory measures. No human exposure or clinical efficacy study has established what that mechanism means for a patient receiving KLOW.

Is KLOW better than GLOW?

There is no clinical evidence that KLOW is better. No trial has tested either finished blend, and none has compared four components against three. KLOW may be the more coherent formulation when a prescriber considers KPV's preclinical rationale relevant, while GLOW omits that component. This is a formulation difference, not a proven ranking.

Have the KLOW or GLOW blends been studied in people?

No published human trial has tested KLOW or GLOW as a finished blend. Their evidence comes from studies of individual components, often in cells or animals and sometimes in a different delivery form. Findings for one ingredient cannot establish the finished mixture's stability, exposure, interactions, safety, or clinical effect.

Can I order GLOW from Promise now?

GLOW is currently waitlist-only at Promise because its intake pathway is not live. KLOW is available now through a prescription pathway. Availability does not establish that one blend is more effective; it only determines whether a provider can presently review a request and, when medically appropriate, write a prescription for that formulation.

KLOW vs GLOW: What KPV Adds to the Blend

KLOW vs GLOW comes down to one ingredient: KPV. GLOW contains BPC-157, TB-500, and GHK-Cu. KLOW contains that same three-peptide core plus KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. The extra component adds a preclinical inflammation rationale, not proof that KLOW works better. No clinical trial has tested either blend, and no head-to-head study has compared them.

That makes the practical question narrower than the names suggest: does KPV's early evidence belong in the formulation a prescriber is considering?

KLOW vs GLOW at a glance

The blends overlap more than they differ. Their shared base is identical; KPV is the fourth component that changes KLOW's evidence story. The full KLOW profile and full GLOW profile cover each formula on its own terms.

	GLOW	KLOW
Components	BPC-157 + TB-500 + GHK-Cu	BPC-157 + TB-500 + GHK-Cu + KPV
Distinguishing component	None beyond the shared core	KPV
Evidence for the blend itself	No clinical trial	No clinical trial
Promise availability	Waitlist only	Available now by prescription

The names do not establish a hierarchy. KLOW is not a higher-strength GLOW, and GLOW is not a diluted KLOW. They are different compounded formulations, separated by one ingredient and the uncertainties that come with it.

What KPV adds to KLOW

KPV stands for lysine-proline-valine. These are the final three amino acids—positions 11 through 13—of alpha-melanocyte-stimulating hormone. Researchers separated this short sequence because it retained an inflammation-related signal without simply reproducing the parent hormone's full set of actions.

The clearest mechanism study used human intestinal epithelial cell lines, a human T-cell line, and two mouse colitis models. KPV entered cells through the PepT1 peptide transporter, reduced activation of NF-kappaB and MAP-kinase pathways, and reduced pro-inflammatory cytokine secretion. In mice with chemically induced colitis, inflammatory measures also fell (Dalmasso et al., Gastroenterology 2008).

A separate 2008 study tested KPV in two other murine colitis systems. Treated mice had less inflammatory infiltration and lower colonic myeloperoxidase activity; the effect persisted in animals with a nonfunctional melanocortin-1 receptor, suggesting that KPV's action was at least partly independent of that receptor (Kannengiesser et al., Inflammatory Bowel Diseases 2008).

Those are meaningful laboratory findings, but they are not clinical outcomes. In its review prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting, the FDA reported that it found no clinical studies or human exposure data for KPV by any route. KPV therefore adds a plausible inflammatory-signaling layer to KLOW; it does not add demonstrated human efficacy. The KPV evidence guide follows that distinction in more depth.

BPC-157, TB-500, and GHK-Cu sit in both formulations. That matters because most of what someone may associate with either blend comes from this shared core, not from KPV. It also means that adding KPV cannot tell us whether the four ingredients remain stable together, change one another's exposure, or produce a combined effect greater than any component alone. Those questions require studies of the finished mixture.

The evidence remains component by component. A 2026 orthopaedics review mapped BPC-157, TB-500, and GHK-Cu to different laboratory pathways involving angiogenesis, extracellular-matrix remodeling, and fibroblast activity, while also noting the current lack of clinical trials (Rahman et al., JAAOS Global Research & Reviews 2026). No published trial has evaluated GLOW's three-part formula or KLOW's four-part formula as a blend.

This is why words such as “synergy” overreach. Mechanisms can explain why ingredients were placed together. Only comparative data can show that the combination delivers an added clinical result.

When GHK-Cu is the narrower question

GHK-Cu is already present in both GLOW and KLOW. If the main clinical question centers on that copper-binding peptide rather than the wider recovery blend, a prescriber may consider whether a single-compound formulation is the cleaner way to evaluate it. The GHK-Cu profile separates its cell, animal, cosmetic, and compounded evidence so findings from one form are not casually transferred to another.

That narrower option matters in a fair comparison. Choosing between GLOW and KLOW is not the only possible decision; sometimes the medically coherent choice is one component, and sometimes it is no peptide prescription at all.

How a prescriber reasons through the difference

There is no evidence-based rule that assigns one blend to a diagnosis. A prescriber's reasoning is more modest: define the goal, identify which component literature is relevant, and decide whether adding an ingredient with no human data makes the formulation more coherent or simply more complex.

Question	Why it matters
Is KPV central to the rationale?	KPV is the only compositional difference between the blends.
How much uncertainty is acceptable?	Neither blend has clinical-trial data, and KPV has no human exposure study.
Would one component answer the narrower question?	A simpler formulation avoids assuming that more ingredients are necessarily better.
Are there relevant conditions or medications?	The reviewing provider needs the whole history to assess fit and uncertainty.
Is the chosen product currently orderable?	GLOW remains waitlist-only at Promise; KLOW has an active prescription pathway.

This reasoning does not produce a universal winner. KLOW may be considered when KPV's preclinical inflammatory mechanism is material to the clinical discussion. GLOW keeps the three-component base without KPV, but its lack of a human blend trial is the same kind of limitation.

Availability and the prescription boundary

KLOW is available through Promise now. GLOW is waitlist-only because its intake pathway is not yet live; the GLOW product page is the place to register interest, not a purchase page. That practical difference may settle timing, but it does not turn availability into evidence.

KLOW and GLOW are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket verification for safety, effectiveness, or quality. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision belongs to the patient and doctor.

At Promise, a licensed provider reviews every request and may prescribe only when medically appropriate; not everyone qualifies.

The useful answer is not “more”

KPV is a real compositional difference with a specific preclinical record. It is not a human-tested upgrade. A careful KLOW-versus-GLOW decision therefore rests on whether that uncertainty is relevant to the goal being reviewed, not on the assumption that four peptides must outperform three.